TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K, Xu J, Su X, Xu Z, Li B, Liu G, Liu H, Wang Y, Zhu Y, Xu L, Zhang W, Liu Z, Wang Z, Chang Y, Xu J.
Jin K, et al. Among authors: wang z, wang y.
J Pathol. 2024 Jun;263(2):139-149. doi: 10.1002/path.6266. Epub 2024 Feb 21.
J Pathol. 2024.
PMID: 38380548